Classification of deprescribing and its use in an elderly patient with cognitive impairment


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Deprescribing antihypertensive agents is a planned or situational process of discontinuation, replacement, and dose reduction, which is adequately controlled by a physician. The paper considers a case of deprescribing using the STOPP/ START criteria and expert evaluation in the hospital, and also provides a comparative assessment of the patients data at the hospital admission and before his discharge.

全文:

受限制的访问

作者简介

G. Krasnov

Samara State Medical University, Ministry of Health of Russia

S. Bulgakova

Samara State Medical University, Ministry of Health of Russia

E. Treneva

Samara State Medical University, Ministry of Health of Russia

N. Zakharova

Samara State Medical University, Ministry of Health of Russia

A. Nikolaeva

Samara State Medical University, Ministry of Health of Russia

O. Rozhdestvenskaya

Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Biomedical Agency of Russia

参考

  1. Сычев Д.А. Полипрагмазия в клинической практике: проблема и способы решения. Учебное пособие, 2-е изд., испр. и доп. СПб: ЦОП «Профессия», 2018; 272 с
  2. Martin-Perez M., Lopez de Andres A., Hernandez-Barrera V. et al. Prevalence of polypharmacy among the population older than 65 years in Spain: Analysis of the 2006 and 2011/12 National Health Surveys. [Article in Spanish]. Rev Esp Geriatr Gerontol. 2017; 52 (1): 2-8. doi: 10.1016/j.regg.2016.07.006
  3. Депрескрайбинг ингибиторов протонной помпы у пациентов пожилого и старческого возраста. Проект протокола [Depreskraibing ingibitorov protonnoi pompy u patsientov pozhilogo i starcheskogo vozrasta. Proekt protokola (in Russ.)]. URL: https://rgnkc.ru/images/pdf_documets/Depreskraibing/Depreskraibing_2_0_1.pdf
  4. Fick D.M., Semla T.P., Steinman M. et al. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J. Am Geriatr Soc. 2019; 67 (4): 674-94. doi: 10.1111/jgs.15767
  5. O’Mahony D., O’Sullivan D., Byrne S. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014; 44 (2): 213-8. doi: 10.1093/ageing/afu145
  6. Pazan F., Weiss C., Wehling M. FORTA. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018; 35 (1): 61-71. DOI: 10.1007/ s40266-017-0514-2
  7. Warle-van Herwaarden M.F., Kramers C., Sturkenboom M.C. et al. Dutch HARM-Wrestling Task Force. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. Drug Saf. 2012; 35 (3): 245-59. doi: 10.2165/11596000-000000000-00000
  8. Koponen M., Taipale H., Lavikainen P. et al. Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer’s disease. J. Alzheimers Dis. 2017; 56: 107-18. doi: 10.3233/JAD-160671
  9. Koponen M., Taipale H., Tanskanen A. et al. Long-term use of antipsychotics among community-dwelling persons with Alzheimers disease: A nationwide register-based study. Eur Neuropsychopharmacol. 2015; 25: 1706-13. doi: 10.1016/j.euroneuro.2015.07.008
  10. Liperoti R., Sganga F., Landi F. et al. Antipsychotic drug interactions and mortality among nursing home residents with cognitive impairment. J. Clin Psychiatry. 2017; 78: e76-e82. doi: 10.4088/JCP.15m10303
  11. Pariente A., Fourrier-Reglat A., Ducruet T. et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012; 172 (8): 648-53. doi: 10.1001/archinternmed.2012.28
  12. Proton Pump Inhibitors - How much for how long? URL: https://www.veteransmates.net.au/topic-32
  13. Garfinkel D., Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010; 170: 1648-54. doi: 10.1001/archinternmed.2010.355
  14. Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and safety. Ther Adv Drug Saf. 2017; 9 (1): 25-43. doi: 10.1177/2042098617736192

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2021